Introduction to ACIP’s Maternal/Pediatric RSV Work Group

Sarah S. Long, MD
Chair, Maternal/Pediatric RSV Work Group

ACIP General Meeting
January 12, 2022
Purpose of the Work Group

- Respiratory syncytial virus (RSV) is a major cause of lower respiratory illness, particularly among infants and children and among older adults and adults with chronic medical conditions.
- RSV vaccine and monoclonal antibody development has progressed in the past decade with over 40 candidate vaccines and monoclonal antibodies currently in development.
- Target populations for whom these products are intended include infants and young children, pregnant women, and older adults.
Work Group Activities

- Consider recommendations for use of RSV vaccines and monoclonal antibodies targeting protection of children aged <18 years:
  - Review the epidemiology and burden of RSV disease in children and pregnant women
  - Review efficacy, immunogenicity, safety and cost-effectiveness of RSV vaccine(s) and newly developed monoclonal antibody products in pregnant women and children
  - Provide evidence-based recommendations regarding use of RSV vaccine(s) and newly developed monoclonal antibody products in pregnant women and children
  - Identify areas in need of further research for informing potential future vaccine and monoclonal antibody recommendations.
RSV Vaccine and Monoclonal Antibody Products that are FDA-Approved or in Development

<table>
<thead>
<tr>
<th>TARGET INDICATION: P = PEDIATRIC</th>
<th>M = MATERNAL</th>
<th>E = ELDERLY</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRECLINICAL</td>
<td>PHASE 1</td>
<td>PHASE 2</td>
</tr>
<tr>
<td>LIVE-ATTENUATED/CHIMERIC</td>
<td>LIVE/NIAD/NIH</td>
<td>Codagenix, LID/NIAD/NIH</td>
</tr>
<tr>
<td></td>
<td>PIV3-NSV</td>
<td>RSV</td>
</tr>
<tr>
<td>PROTEIN-BASED - INACTIVATED</td>
<td>Phase 1</td>
<td>Phase 2</td>
</tr>
<tr>
<td>PARTICLE - SUBUNIT</td>
<td>Live/NIAD/NIH</td>
<td>Intervax</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RSV-17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sanofi Vaccine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LID/NIAD/NIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LID/NIAD/NIH</td>
</tr>
<tr>
<td>PROTEIN-BASED - INACTIVATED</td>
<td>Phase 2</td>
<td>Phase 3</td>
</tr>
<tr>
<td>PARTICLE - SUBUNIT</td>
<td>Live/NIAD/NIH</td>
<td>Seno, LID/NIAD/NIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RSV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RSV</td>
</tr>
<tr>
<td>NUCLEIC ACID</td>
<td>Phase 3</td>
<td>Phase 1</td>
</tr>
<tr>
<td>RECOMBINANT VECTORS</td>
<td>Moderna</td>
<td>CoreVacc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RNA</td>
</tr>
<tr>
<td>IMMUNOPROPHYLAXIS</td>
<td>Phase 2</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td>Bavarian Nordic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Janssen Pharmaceutical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Janssen Pharmaceutical</td>
</tr>
</tbody>
</table>

UPDATED: September 28, 2021

https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/
RSV Vaccine and Monoclonal Antibody Products in Phase 3 Trials

- GlaxoSmithKline: RSV F Protein
- Pfizer: RSV F Protein
- AstraZeneca, Sanofi: Anti-F mAb
- Merck: Anti-F mAb

P = PEDIATRIC  M = MATERNAL  E = ELDERLY
Work Group Members

**ACIP Members**
Sarah Long (chair)
Pablo Sanchez
Oliver Brooks

**Ex Officio Members**
Rachel Zhang (FDA-CBER)
Jaya Goswami (FDA-CBER)
Judy Beeler (FDA-CBER)
Yodit Belew (FDA-CDER)
Prabha Viswanathan (FDA-CDER)
Samer El-Kamary (FDA-CDER)
Sonnie Kim (NIH-NIAID)
April Killikelly (Public Health Agency of Canada)

**Consultants**
Denise Jamieson (Emory University School of Medicine)
Cody Meissner (Tufts Medical Center)
Helen Chu (University of Washington)
Daniel Feikin (World Health Organization)

**Liaisons**
Carol Baker (IDSA)
Patsy Stinchfield (NFID)
Brenna L. Hughes (ACOG)
Nicole Chaisson (AAFP)
Sean O-Leary (AAP)

**CDC staff:**
Jefferson Jones (lead)
Respiratory Viral Branch
Angie Campbell
Meredith McMorrow
Mila Prill
Fiona Havers
Natalie Thornburg
Adam Macneil

Immunization Safety Office
Christine Olson
Anne Hause
Immunizations Service Division
Patricia Wodi
Neil Murthy
Work Group Calls

- Held in October 2021–January 2022
  - Reviewed burden and epidemiology of RSV
  - Reviewed U.S. RSV surveillance systems and definitions of RSV infection and disease
  - Discussed potential components of cost effectiveness considerations for RSV vaccines and mAb products
Upcoming Work Group Activities

- Review safety and efficacy with manufacturers of vaccines and mAb
- Review RSV seasonality data in relation to potential recommendations for timing of administration of vaccines and mAb product
- Review results of cost effectiveness model
- Present data to ACIP
- Apply Evidence to Recommendation Framework for each product

The first vote by ACIP is not expected until 2023.
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.